USP Establishes Elemental Impurities Implementation Dates

News
Article

USP announces an implementation date of Jan. 1, 2018 for General Chapters Elemental Impurities-Limits and Elemental Contaminants in Dietary Supplements.

 

The United States Pharmacopeial Convention (USP) announced on Mar. 31, 2015 that it would establish Jan. 1, 2018 as the implementation date for General Chapters <232> Elemental Impurities-Limits and <2232> Elemental Contaminants in Dietary Supplements in USP’s compendia of public standards, United States Pharmacopeia–National Formulary (USP–NF). The announcement also confirmed that USP would remove General Chapter <231> Heavy Metals from USP–NF, and monograph references to this chapter will be delayed until the aforementioned date in 2018.

Users may continue to use the current approach or implement the new 232/2232 approaches until Jan. 1, 2018, on which date the General Chapters will be required unless otherwise specified in a monograph. USP revised General Notices Section 5.60.30 Elemental Impurities in USP Drug Products and Dietary Supplements in USP–NF following the December 2014 release of the International Conference on Harmonization (ICH) Q3D Guideline for Elemental Impurities, and based on dialogue with industry representatives and FDA. The revisions are official as of Apr. 1, 2015 and are listed in the press release as follows:

  • Specify the timing of the applicability of General Chapters <232> and <2232> for Jan. 1, 2018 to align more closely with the implementation date of the ICH Q3D guideline for existing products.

  • Note the delay in omission of General Chapter <231> Heavy Metals until Jan. 1, 2018 to align with the applicability of <232>.

  • Allow early adoption of the General Chapters <232> and <2232> in the interim to enable users to determine whether to use the existing <231> or the new <232>/<2232> approaches.

Source: USP

 

Recent Videos
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.